CA-NETAPP
15.11.2021 14:02:11 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, announced the extension of its partnership with the Ducati Corse motorcycle racing team at the completion of the 2021 MotoGP World Championship race in Valencia, Spain. For the next two years, NetApp will continue to help advance Ducati’s performance in the MotoGP World Championship, the world’s most prestigious motorcycle racing competition.
The collaboration between Ducati (part of the Volkswagen Group), through its Ducati Corse division, and NetApp began in 2018 in a bid to maximize the use of data to improve performance within the world of racing. NetApp and Ducati are expanding their work together to accelerate digital transformation by:
- Optimizing 3D product design in complex development projects by implementing a new virtual desktop environment, allowing engineers to collaborate efficiently all over the world. As part of this improvement, engineers and developers can securely leverage and archive any project data, using the rich functionalities of NetApp StorageGRID object storage.
- Automating the racing team’s data workflow before, during and after the race. Engineers can support their team’s success, both remotely and on-site to maximize the power of information for the win.
- Supporting the overall evolution of the information technology strategy through collaboration between Ducati and the Professional Services teams at NetApp.
“We are delighted to build on the collaboration with NetApp, which has developed well over the past four years,” said Luigi Dall'Igna, General Manager at Ducati Corse. “We look forward to working together to continue to optimize our performance with the limitless possibilities that the power of data can bring to the motorbike racing world.”
“Leading a winning team requires exploring new ways to succeed and finding any edge to beat the competition,” said Cesar Cernuda, President at NetApp. “Our partnership and momentum with Ducati Corse are thriving and the team secured three of the top five placements in world standings this year. We are proud to support the ongoing digital transformation of Ducati into a winning, data-driven company.”
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
About Ducati
Founded in 1926, since 1946 Ducati has been manufacturing sport-inspired motorcycles characterised by high-performance engines, innovative design and cutting-edge technology. Ducati factory is located in Bologna’s Borgo Panigale district. The model range covers several market segments with the following families: Diavel, XDiavel, Hypermotard, Monster, Multistrada, SuperSport, Panigale and Streetfighter. In 2015, Ducati presented the Ducati Scrambler: a new brand made of bikes, accessories and apparel that that stands out for its creativity and self-expression. In 2020 Ducati unveiled the Multistrada V4, the world's first motorcycle equipped with front and rear radar, which with its technology marks a new milestone for the world of two wheels. Ducati iconic motorcycles, together with an extensive range of bike accessories and technical and lifestyle apparel, are distributed in 90 countries worldwide. In 2020 Ducati delivered 48,042 bikes to customers. Ducati competes in both MotoGP and Superbike World Championships. The Company has been racing in the MotoGP category since 2003 and has won the Constructors' World Title in 2020 and 2021. Furthermore, Ducati was World Champion in the 2007 season, winning both Constructors' and Riders' Title. In Superbike, Ducati has won 17 Manufacturer's Titles and 14 Rider's Titles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom